These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34610281)

  • 1. P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats.
    Xu Y; Lu J; Yao B; Zhang Y; Huang S; Liu J; Zhang Y; Guo Y; Wang X
    Toxicol Appl Pharmacol; 2021 Nov; 431():115735. PubMed ID: 34610281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics.
    Pinto L; Moreira FL; Nardotto GHB; Cavalli RC; Moisés ECD; Duarte G; Lanchote VL
    Pharm Res; 2020 Jun; 37(7):131. PubMed ID: 32557079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of fluoxetine on olanzapine pharmacokinetics.
    Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
    AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
    Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
    Trivedi MH; Thase ME; Osuntokun O; Henley DB; Case M; Watson SB; Campbell GM; Corya SA
    J Clin Psychiatry; 2009 Mar; 70(3):387-96. PubMed ID: 19284928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative bioavailability of a new formulation of fluoxetine drops.
    Floriddia ML; Castorina M; Drago F
    Eur Rev Med Pharmacol Sci; 2000; 4(1-2):9-13. PubMed ID: 11409190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
    J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.
    Zang YN; Dong F; Li AN; Wang CY; Guo GX; Wang Q; Zhang YF; Zhang L; de Leon J; Ruan CJ
    Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):353-371. PubMed ID: 33677821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
    Zhang W; Perry KW; Wong DT; Potts BD; Bao J; Tollefson GD; Bymaster FP
    Neuropsychopharmacology; 2000 Sep; 23(3):250-62. PubMed ID: 10942849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.
    Seager MA; Barth VN; Phebus LA; Rasmussen K
    Psychopharmacology (Berl); 2005 Aug; 181(1):126-33. PubMed ID: 15719213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers.
    Vlase L; Leucuta A; Farcau D; Nanulescu M
    Biopharm Drug Dispos; 2006 Sep; 27(6):285-9. PubMed ID: 16770757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis.
    Horowitz JM; Goyal A; Ramdeen N; Hallas BH; Horowitz AT; Torres G
    Synapse; 2003 Dec; 50(4):353-64. PubMed ID: 14556240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
    Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
    J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of drug-in-adhesive patch formulations for transdermal delivery of fluoxetine: In vitro and in vivo evaluations.
    Jung E; Lee EY; Choi HK; Ban SJ; Choi SH; Kim JS; Yoon IS; Kim DD
    Int J Pharm; 2015 Jun; 487(1-2):49-55. PubMed ID: 25863117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
    Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
    Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
    Sun L; von Moltke L; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2020 Feb; 9(2):106-114. PubMed ID: 31919994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions.
    Fan L; Zhang L; Zheng H; Cheng J; Hu Y; Liu J; Fan H
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):593-601. PubMed ID: 32413238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.
    Zanarini MC; Frankenburg FR; Parachini EA
    J Clin Psychiatry; 2004 Jul; 65(7):903-7. PubMed ID: 15291677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption.
    Uhr M; Steckler T; Yassouridis A; Holsboer F
    Neuropsychopharmacology; 2000 Apr; 22(4):380-7. PubMed ID: 10700657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.